Krystal Biotech (KRYS) EBIAT (2021 - 2025)
Historic EBIAT for Krystal Biotech (KRYS) over the last 5 years, with Q4 2025 value amounting to $51.4 million.
- Krystal Biotech's EBIAT rose 1301.92% to $51.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $204.8 million, marking a year-over-year increase of 12973.68%. This contributed to the annual value of $204.8 million for FY2025, which is 12973.68% up from last year.
- Per Krystal Biotech's latest filing, its EBIAT stood at $51.4 million for Q4 2025, which was up 1301.92% from $79.4 million recorded in Q3 2025.
- Krystal Biotech's 5-year EBIAT high stood at $80.7 million for Q3 2023, and its period low was -$50.0 million during Q1 2022.
- For the 5-year period, Krystal Biotech's EBIAT averaged around $4.8 million, with its median value being -$7.3 million (2021).
- Per our database at Business Quant, Krystal Biotech's EBIAT crashed by 21599.42% in 2022 and then skyrocketed by 373401.29% in 2025.
- Quarter analysis of 5 years shows Krystal Biotech's EBIAT stood at -$21.8 million in 2021, then crashed by 46.99% to -$32.1 million in 2022, then skyrocketed by 127.12% to $8.7 million in 2023, then soared by 423.23% to $45.5 million in 2024, then grew by 13.02% to $51.4 million in 2025.
- Its EBIAT stands at $51.4 million for Q4 2025, versus $79.4 million for Q3 2025 and $38.3 million for Q2 2025.